AdAlta Ltd

  AdAlta (ASX:1AD) has announced the receipt of a $1.77 million Research and Development Tax Incentive (“RDTI”) refund in respect of the financial year to 30 June 2024 | ASX announcement: https://lnkd.in/gRrN8mxD

Australian researchers have made a significant breakthrough in understanding pulmonary fibrosis. They've developed a standardized way to assess environmental exposures in patients, which could lead to better diagnosis and treatment.

Teletrials are making a big difference in clinicla trials for pulmornary fibrosis. By using technology, patients can participate from the comfort of their homes, increasing enrollment and speeding up the process. This means faster advancements in treatments and better outcomes for people living with PF.

Walking is a valuable excercise for individuals with pulmonary fibrosis. It can help improve lung function, increase endurance and enhance overall quality of life. If you have pulmonary fibrosis, consult with your healthcare provide to discuss how walking can be incorporated into your excercise regimen.

New research suggests the simple sit-to-stand test can be a valuable tool for screening pulmonary fibrosis patients.

BIOSHARES has penned an insightful article about AdAlta’s strategy to commercialise its suite of singe domain antibodies (i-bodies). The article highlights the important role two special purpose vehicles are playing in delivering this strategy. The first is AdSolis, which houses lead drug candidate AD-214 which is heading towards Phase II clinical trials. The second is the AdCella subsidiary executing an 'East to West Reverse Innovation Strategy & Business Model’ for cellular immunotherapies, harnessing Asia innovation, Australian capabilities and with AdAlta's i-body® platform.

Australia leads the way in equitable healthcare. While many countries experience sex-and race-based disparities in pulmonary fibrosis treatment, Australia ensures everyone receives the same quality of care.

A BIOSHARES feature article on progress of CAR-T cell therapy concludes in part that breakthroughs against solid tumours will likely generate larger deals; China will remain active in the CAR-T field; and this supports AdAlta’s strategy of seeking to license immune-oncology assets for solid cancers from China for use in western biotech markets including the US and Europe. 

New therapies to stop progression of IPF are desperately needed – this why AdAlta and others are working so hard to identify new approaches.

New research highlights the urgent need for international collaboration to address disparities in health outcomes for patients with pulmonary fibrosis.